Professor P-O Berggren and his research groups run an impressive list of scientific projects outside those commercialized by Biocrine. The research groups also participate in projects conducted by other groups. In most cases, all these projects result in successful scientific publications. Here is a list of publications generated since 2013: Programmable DNA Scaffolds Enable Orthogonal Engineering …
Aktieägarna i Biocrine AB kallas härmed till årsstämma måndagen den 17 juni 2024 kl 15:00 Plats: Redeye AB, Mäster Samuelsgatan 42, våning 10 sal Dialog, Stockholm. Avstämningsdag: 2024-06-07 Sista anmälningsdag: 2024-06-12 Mer information angående årsstämman finns HÄR.
As has recently been published on the Karolinska Institutet in Sweden’s website, Professor Per-Olof Berggren and his colleagues have developed a method to study liver function and disease without requiring invasive procedures. The study is published in the journal Nature Communications. Read more: News from Karolinska Institutet Nature Communications Ögat används som fönster för att …
On the web-site of Karolinska Institutet, there is a recent press release revealing that Professor Per-Olof Berggren has been awarded a ERC Proof of Concept grant by the European Research Council (ERC). The funding will be used to advance the technology in which islets of Langerhans are transplanted into the anterior chamber of the eye …
As has recently been published on the Karolinska Institutet in Sweden’s website, Professor Per-Olof Berggren and his colleagues have brought new insight into the technology of using the anterior chamber of the eye as a servant to medical research. The relevant knowledge on the ACE technology is now being published in Physiological Reviews. Read more: …
On the web-site of Karolinska Institutet, there is a post of October 2023 revealing that Professor Lisa Juntti-Berggren at Karolinska Institutet is awarded the Swedish Society of Medicine’s Jubilee Prize 2023 for her studies on Apolipoprotein CIII and diabetes mellitus. The awardee is rewarded with SEK 150,000 and the SLS centenary medal in silver. Read …
As was published in October 2023 on the Karolinska Institutet in Sweden’s website, researchers at Karolinska Institutet and KTH Royal Institute of Technology have developed a microscale device for implantation in the eye, which presents new opportunities for cell-based treatment of diabetes and other diseases. The study is published in the journal Advanced Materials. Read …
Aktieägarna i Biocrine AB kallas härmed till årsstämma fredagen den 16 juni 2023 kl 13:00 Plats: Mäster Samuelsgatan 42, våning 10 sal Dialog, Stockholm. Avstämningsdag: 2023-06-08 Sista anmälningsdag: 2023-06-13 Mer information angående årsstämman finns HÄR.
On the web-site of Karolinska Institutet, there is a recent press release regarding a study published in Science Translational Medicine. Read more: Press release in English HIF-1α inhibitor PX-478 preserves pancreatic β cell function in diabetes Ny strategi för att bevara insulinproducerande celler vid diabetes På Karolinska Institutets hemsida finns en nyligen publicerad pressrelease …
Aktieägarna i Biocrine AB kallas härmed till årsstämma tisdagen den 27 juni 2022 kl 15:00 på Mäster Samuelsgatan 42, våning 10 sal Dialog, Stockholm. Avstämningsdag: 2022-06-16 Sista anmälningsdag: 2022-06-22 Mer information angående årsstämman finns HÄR.